Literature DB >> 35570748

Treatment of coronary bifurcation lesions, part I: implanting the first stent in the provisional pathway. The 16th expert consensus document of the European Bifurcation Club.

Remo Albiero1, Francesco Burzotta2, Jens Flensted Lassen3, Thierry Lefèvre4, Adrian P Banning5, Yiannis S Chatzizisis6, Thomas W Johnson7, Miroslaw Ferenc8, Manuel Pan9, Olivier Daremont10, David Hildick-Smith11, Alaide Chieffo12, Yves Louvard4, Goran Stankovic13.   

Abstract

Stepwise layered provisional stenting (PS) is the most commonly used strategy to treat coronary bifurcation lesions (CBL). The term 'stepwise layered' emphasises the versatility of this approach that allows the adjustment of the procedure plan according to the CBL complexity, starting with stent implantation in one branch and implantation of a second stent in the other branch only when required. A series of refinements have been implemented over the years to facilitate the achievement of predictable procedural results using this approach. However, despite its simplicity and versatility, operators using this technique require full knowledge of the pitfalls of each procedural step. Part I of this 16th European Bifurcation Club consensus paper provides a detailed step-by-step overview of the pitfalls and technical troubleshooting during the implantation of the first stent using the PS strategy for the treatment of CBL.

Entities:  

Mesh:

Year:  2022        PMID: 35570748     DOI: 10.4244/EIJ-D-22-00165

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   7.728


  2 in total

1.  Side Branch Late Thrombosis After Left Main Coronary Artery Crossover Stenting.

Authors:  Sultan Alotaibi; Hajo Heyer; Gert Richardt; Abdelhakim Allali
Journal:  Cardiol Ther       Date:  2022-06-30

Review 2.  Impact of coronary bifurcation angle on the pathogenesis of atherosclerosis and clinical outcome of coronary bifurcation intervention-A scoping review.

Authors:  Yoshinobu Murasato; Kyohei Meno; Takahiro Mori; Katsuhiko Tanenaka
Journal:  PLoS One       Date:  2022-08-17       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.